Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 26, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Lamotrigine Orally Disintegrating Tablets USP, 25 mg, 50 mg, 100 mg and 200 mg".